- All sections
- C - Chemistry; metallurgy
- C12N - Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
- C12N 5/078 - Cells from blood or from the immune system
Patent holdings for IPC class C12N 5/078
Total number of patents in this class: 2702
10-year publication summary
144
|
205
|
175
|
225
|
268
|
277
|
301
|
230
|
246
|
82
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Iovance Biotherapeutics, Inc. | 301 |
75 |
Rubius Therapeutics, Inc. | 78 |
40 |
Kyoto University | 2732 |
39 |
Megakaryon Corporation | 49 |
34 |
Cellphire, Inc. | 108 |
27 |
Fenwal, Inc. | 626 |
27 |
FATE Therapeutics, Inc. | 176 |
25 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
22 |
Massachusetts Institute of Technology | 9795 |
20 |
The Regents of the University of California | 18943 |
19 |
Oncotherapy Science, Inc. | 302 |
18 |
President and Fellows of Harvard College | 5792 |
17 |
Children's Medical Center Corporation | 1780 |
17 |
Wisconsin Alumni Research Foundation | 3774 |
16 |
The Trustees of Columbia University in the City of New York | 3440 |
16 |
The General Hospital Corporation | 4517 |
15 |
The Trustees of the University of Pennsylvania | 4122 |
14 |
Mayo Foundation for Medical Education and Research | 2981 |
14 |
Astellas Institute for Regenerative Medicine | 118 |
14 |
Canadian Blood Services | 82 |
14 |
Other owners | 2219 |